Drug Trial Radar · NCT00768274
Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
Last checked: Nov 19, 2026Latest source record: Nov 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Sep 2008
Primary completion
Aug 2009
Study completion Aug 2009
Sponsor
- Lead sponsor
- Resverlogix CorpIndustry
- Sponsor type
- Industry
- First posted
- Oct 8, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate an oral formulation of RVX000222 for safety, pharmacokinetic and efficacy in healthy subjects.
Conditions
- Dyslipidemia
- Atherosclerosis
- Acute Coronary Syndrome
- Cardiovascular Disease
Interventions
RVX000222Drug
RVX000222 twice daily (b.i.d.) for 28 days
PlaceboDrug
Placebo twice daily (b.i.d.) for 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety, pharmacokinetics and changes in lipid parameters from baseline and placebo.Time frame: 1-month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Unit, Inc.
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.